<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04574141</url>
  </required_header>
  <id_info>
    <org_study_id>Pil-Clin-Melat-020</org_study_id>
    <nct_id>NCT04574141</nct_id>
  </id_info>
  <brief_title>Kinetic of Melatonin Subsequent to the Consumption of Melatonin-rich Food Supplements</brief_title>
  <official_title>Randomized, Open-label Bioavailability Study of the Kinetics of Plasma, Urinary and Salivary Concentrations of Melatonin and 6-sulfatoxymelatonin Subsequent to the Consumption of Melatonin-rich Food Supplements With Different Galenic Forms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PiLeJe</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Larena SAS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to clinically document the melatonin bioavailability of two dietary&#xD;
      supplements containing melatonin : one prolonged release tablet dosed at 1.9mg and one spray&#xD;
      dosed at 1mg for 2 oral sprays.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 13, 2020</start_date>
  <completion_date type="Actual">October 5, 2020</completion_date>
  <primary_completion_date type="Actual">October 5, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evolution of the plasma melatonin concentration</measure>
    <time_frame>over 540 minutes after taking the sustained-release tablet and 420 minutes after taking the spray.</time_frame>
    <description>the change in plasma melatonin concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>evolution of the plasma concentration of 6-sulfatoxymelatonin</measure>
    <time_frame>over 540 minutes after taking the sustained-release tablet and 420 minutes after taking the spray.</time_frame>
    <description>the change in plasma 6-sulfatoxymelatonin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evolution of the urinary concentration of 6-sulfatoxymelatonin</measure>
    <time_frame>over 540 minutes after taking the sustained-release tablet and 420 minutes after taking the spray.</time_frame>
    <description>the change in urinary 6-sulfatoxymelatonin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evolution of the salivary concentration of melatonin</measure>
    <time_frame>over 540 minutes after taking the sustained-release tablet and 420 minutes after taking the spray.</time_frame>
    <description>the change in salivary melatonin concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>during study participation, maximum 45 days</time_frame>
    <description>adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma melatonin AUC</measure>
    <time_frame>over 540 minutes after taking the sustained-release tablet and 420 minutes after taking the spray.</time_frame>
    <description>Area Under the Curve of plasma melatonin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma 6-sulfatoxymelatonin AUC</measure>
    <time_frame>over 540 minutes after taking the sustained-release tablet and 420 minutes after taking the spray.</time_frame>
    <description>Area Under the Curve of plasma 6-sulfatoxymelatonin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary 6-sulfatoxymelatonin AUC</measure>
    <time_frame>over 540 minutes after taking the sustained-release tablet and 420 minutes after taking the spray.</time_frame>
    <description>Area Under the Curve of urinary 6-sulfatoxymelatonin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>salivary melatonin AUC</measure>
    <time_frame>over 540 minutes after taking the sustained-release tablet and 420 minutes after taking the spray.</time_frame>
    <description>Area Under the Curve of salivary melatonin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma melatonin Cmax</measure>
    <time_frame>over 540 minutes after taking the sustained-release tablet and 420 minutes after taking the spray.</time_frame>
    <description>Peak concentration of plasma melatonin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma 6-sulfatoxymelatonin Cmax</measure>
    <time_frame>over 540 minutes after taking the sustained-release tablet and 420 minutes after taking the spray.</time_frame>
    <description>Peak concentration of plasma 6-sulfatoxymelatonin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary 6-sulfatoxymelatonin Cmax</measure>
    <time_frame>over 540 minutes after taking the sustained-release tablet and 420 minutes after taking the spray.</time_frame>
    <description>Peak concentration of urinary 6-sulfatoxymelatonin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>salivary melatonin Cmax</measure>
    <time_frame>over 540 minutes after taking the sustained-release tablet and 420 minutes after taking the spray.</time_frame>
    <description>Peak concentration of salivary melatonin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma melatonin Tmax</measure>
    <time_frame>over 540 minutes after taking the sustained-release tablet and 420 minutes after taking the spray.</time_frame>
    <description>Time take to reach Cmax of plasma melatonin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma 6-sulfatoxymelatonin Tmax</measure>
    <time_frame>over 540 minutes after taking the sustained-release tablet and 420 minutes after taking the spray.</time_frame>
    <description>Time take to reach Cmax of plasma 6-sulfatoxymelatonin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary 6-sulfatoxymelatonin Tmax</measure>
    <time_frame>over 540 minutes after taking the sustained-release tablet and 420 minutes after taking the spray.</time_frame>
    <description>Time take to reach Cmax of urinary 6-sulfatoxymelatonin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>salivary melatonin Tmax</measure>
    <time_frame>over 540 minutes after taking the sustained-release tablet and 420 minutes after taking the spray.</time_frame>
    <description>Time take to reach Cmax of salivary melatonin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma melatonin half life</measure>
    <time_frame>over 540 minutes after taking the sustained-release tablet and 420 minutes after taking the spray.</time_frame>
    <description>time required for the concentration of plasma melatonin to decrease to half of its starting dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma 6-sulfatoxymelatonin half life</measure>
    <time_frame>over 540 minutes after taking the sustained-release tablet and 420 minutes after taking the spray.</time_frame>
    <description>time required for the concentration of plasma 6-sulfatoxymelatonin to decrease to half of its starting dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary 6-sulfatoxymelatonin half life</measure>
    <time_frame>over 540 minutes after taking the sustained-release tablet and 420 minutes after taking the spray.</time_frame>
    <description>time required for the concentration of urinary 6-sulfatoxymelatonin to decrease to half of its starting dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>salivary melatonin half life</measure>
    <time_frame>over 540 minutes after taking the sustained-release tablet and 420 minutes after taking the spray.</time_frame>
    <description>time required for the concentration of salivary melatonin to decrease to half of its starting dose</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Melatonin Bioavailability</condition>
  <arm_group>
    <arm_group_label>spray before tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>tablet before spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>a prolonged release tablet and a spray containing melatonin</intervention_name>
    <description>prolonged release tablet is dosed at 1.9mg and spray is dosed at 1mg for 2 oral sprays.</description>
    <arm_group_label>spray before tablet</arm_group_label>
    <arm_group_label>tablet before spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male between the ages of 18 and 45,&#xD;
&#xD;
          -  In good general health, i.e., free of chronic conditions and not taking medication at&#xD;
             the time of inclusion and/or long-term,&#xD;
&#xD;
          -  Over 70 kg and with a body mass index between 18.5 and 24.9,&#xD;
&#xD;
          -  Able and willing to participate in the research by complying with the procedures of&#xD;
             the protocol, in particular concerning the taking of the product under study and the&#xD;
             performance of sequential blood tests,&#xD;
&#xD;
          -  Having freely signed the consent form after adequate information on the proposed&#xD;
             study, in accordance with Good Clinical Practice and after submission of the&#xD;
             information leaflet,&#xD;
&#xD;
          -  Affiliated to a social security scheme or similar.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smoker,&#xD;
&#xD;
          -  Drug addict,&#xD;
&#xD;
          -  Subject with an alcohol consumption of more than 2 glasses per day,&#xD;
&#xD;
          -  Taking a drug treatment or melatonin or a product containing melatonin within 48 hours&#xD;
             prior to a kinetics visit,&#xD;
&#xD;
          -  Known organic or functional abnormality of the urinary tree,&#xD;
&#xD;
          -  Any medical condition that would involve a change in melatonin metabolism:&#xD;
&#xD;
        Drug intake: Fluvoxamine, 5- or 8-methoxypsoralen, cimetidine, carbamazepine and&#xD;
        rifampicin, analgesics, Liver abnormality known or detected at the screening visit and&#xD;
        judged to be clinically significant by the investigator, Known autoimmune disease,&#xD;
&#xD;
          -  Subject assessed as &quot;moderately&quot; or &quot;definitely&quot; evening type,&#xD;
&#xD;
          -  Known hypertension (&gt;140/90),&#xD;
&#xD;
          -  Diagnosis of migraine by a health professional according to the International Headache&#xD;
             Society (IHS) criteria revised in 2004,&#xD;
&#xD;
          -  Wuth a sleep disorder,&#xD;
&#xD;
          -  Thyroid dysfunction, hyperglycemia or anemia judged to be clinically significant by&#xD;
             the investigator,&#xD;
&#xD;
          -  Blood donation within one month prior to inclusion,&#xD;
&#xD;
          -  A known organic or psychological abnormality (including a history of severe&#xD;
             depression) that may bias the results of the study as judged by the investigator,&#xD;
&#xD;
          -  Workers with atypical working hours (night work, staggered working hours),&#xD;
&#xD;
          -  Known allergy or intolerance to any of the components of the product,&#xD;
&#xD;
          -  Psychological or linguistic inability to understand and sign informed consent,&#xD;
&#xD;
          -  Participant in another interventional clinical trial or during a period of exclusion&#xD;
             from a previous clinical trial,&#xD;
&#xD;
          -  Under legal protection (guardianship, curatorship) or deprived of his rights as a&#xD;
             result of the administrative or judicial decision,&#xD;
&#xD;
          -  Subject who has reached the maximum threshold for compensation for research provided&#xD;
             for in the regulations.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Claustrat</last_name>
    <role>Study Director</role>
    <affiliation>PiLeJe</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CIC CEN EXPERIMENTAL / CEN Nutriment</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 27, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no sharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

